What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
PALM-PAH study design and Phase 2b topline results in pulmonary arterial hypertension, at the Pulmonary Vascular Research Institute 2026 congress. Alongside this, new analyst coverage from a major investment bank underscores how TPIP and Insmed's broader respiratory and rare disease pipeline are shaping the company's profile in pulmonary medicine. Against this backdrop, we will examine how Insmed's upcoming TPIP data disclosures could influence its investment narrative and long-term positioning. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave To own Insmed, you have to be comfortable backing a high-spend, high-potential respiratory and rare disease platform where ARIKAYCE and brensocatib are already central, and TPIP is emerging as a third pillar. The upcoming TPIP presentations at PVRI 2026 matter because they sharpen expectations around the Phase 3 PALM-PAH program and could shift what investors view as the key near-term c
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (NASDAQ:INSM) had its price target raised by analysts at Morgan Stanley from $157.00 to $162.00. They now have an "equal weight" rating on the stock.MarketBeat
- Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions [Yahoo! Finance]Yahoo! Finance
- Insmed (NASDAQ:INSM) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 CongressPR Newswire
- Insmed (NASDAQ:INSM) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 1/22/26 - Form 4
- 1/21/26 - Form SCHEDULE
- 1/20/26 - Form 144
- INSM's page on the SEC website